Risk-MaPP, ADEs and PDEs: Importance to multi-product pharmaceutical manufacturing facilities

In Episode 22 of the Biopharma EHS podcast, Dean M. Calhoun, CIH, President of Affygility Solutions, interviews Ms. Stephanie Wilkins, President of PharmaConsult US, regarding the topic of Risk-MaPP, ADEs and PDEs: Their importance to multi-product pharmaceutical manufacturing facilities. The interview is approximately 22-minutes long and is available on Affygility SolutionsFacebook page, SoundcloudiTunes, and now on Stitcher. You can also listen via the audio player below:

If you like what you heard, please share it,and if you need either an occupational exposure limit (OEL) or acceptable daily exposure (ADE) value for your active pharmaceutical ingredient, check out the OEL Fastrac catalog for a complete listing of all our occupational exposure limit monographs with ADEs (also known as PDE reports). Purchase online with immediate instant download!


About Dean Calhoun

view all posts

Dean is the President and CEO of Affygility Solutions. Affygility Solutions provides environmental, health and safety software, potent compound safety, industrial hygiene, containment validation services to the pharmaceutical, biotechnology, and medical device industry. "Dean's Google+ Profile"

Affygility Solutions - provider of potent compound safety, webinars, and compliance management software